Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3

Conditions

Papillomavirus Infections 4Uterine Cervical Neoplasms 3Hepatitis B 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Engerix-B × Clear all
NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

GlaxoSmithKline

Phase 3 Completed
152 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

GlaxoSmithKline

Phase 4 Completed
34,412 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
744 enrolled 27 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01082861 2010-03-19

TANGO

National Institute for Public Health and the Environment (RIVM)

Phase 4 Terminated

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡